Kiniksa Pharmaceuticals International (KNSA) Other Non-Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Other Non-Current Assets for 10 years, with the latest figure at $11.2 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 36.09% year-over-year to $11.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.2 million (up 36.09% YoY), and the FY2025 full-year result was $11.3 million, up 9.62% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $11.2 million, down from $11.3 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $11.3 million in Q4 2025, with the low at $827000.0 in Q4 2023.
• Historically, Other Non-Current Assets has averaged $6.4 million across 5 years, with a median of $5.9 million in 2022.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets sank 85.8% — and 2024, when it soared 1147.28%.
• Kiniksa Pharmaceuticals International's Other Non-Current Assets stood at $5.8 million in 2022, then slumped by 85.8% to $827000.0 in 2023, then soared by 1147.28% to $10.3 million in 2024, then grew by 9.62% to $11.3 million in 2025, then fell by 1.28% to $11.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $11.2 million (Q1 2026), $11.3 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.